PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28436281-2	2018	Roles of human cytochrome P450 (P450) 3A4 in oxidation of an antihistaminic drug terfenadine have been previously investigated in association with terfenadine-ketoconazole interaction.	Terfenadine	81-92	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-41	
28436281-2	2018	Roles of human cytochrome P450 (P450) 3A4 in oxidation of an antihistaminic drug terfenadine have been previously investigated in association with terfenadine-ketoconazole interaction.	Terfenadine	147-158	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	15-41	
9694927-12	1998	These potential dual actions on HERG currents suggest that precautions should be taken in long-term ketoconazole treatment, particularly for patients who have decreased liver function or are on a drug regimen requiring simultaneous medications that use cytochrome-P450 for breakdown, such as terfenadine or erythromycin, or Class III antiarrhythmic drugs.	Terfenadine	292-303	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	253-268	
9694927-2	1998	Both compounds use the same cytochrome-P450 metabolic pathway, resulting in an increase in plasma concentration of terfenadine.	Terfenadine	115-126	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43	
22616812-2	2012	Further, clinically significant interactions with inhibitors of cytochrome P450 (CYP) have previously been reported for drugs of this therapeutic group, such as terfenadine and astemizole, indicating the possibility of drug-drug interactions involving agents that share the same metabolic pathway.	Terfenadine	161-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	64-79	
22616812-2	2012	Further, clinically significant interactions with inhibitors of cytochrome P450 (CYP) have previously been reported for drugs of this therapeutic group, such as terfenadine and astemizole, indicating the possibility of drug-drug interactions involving agents that share the same metabolic pathway.	Terfenadine	161-172	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	81-84	
9270401-2	1997	TDP has been associated with terfenadine use in cases of liver disease, electrolyte abnormalities, concomitant administration of drugs that inhibit cytochrome P-450, or deliberate overdose.	Terfenadine	29-40	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	148-164	
8257958-4	1993	The increased risk of both H1-antihistamines was associated with exposure to supratherapeutic doses; for terfenadine the risk was also associated with concomitant exposure to the cytochrome P-450 inhibitors ketoconazole, erythromycin and cimetidine.	Terfenadine	105-116	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	179-195